3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
21
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
Kidney Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Disease
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Astrocytoma
1
Anemia
1
Interventions
pembrolizumab
3
fludarabine
3
aldesleukin
3
Cyclophosphamide
3
cabozantinib
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
olaparib
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
darolutamide
1
Therapeutics
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Loperamide
1
Geriatric Assessment
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Fecal Microbiota Transplantation
1
Exercise
1
Continuous Positive Airway Pressure
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Pluvicto
×
90 days
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled